A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus
收藏DataCite Commons2025-02-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005588/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a Phase III, randomized, double-blind, placebo-controlled, multicentre, parallel-group study designed to evaluate the efficacy and safety of ocrelizumab added to SOC (corticosteroid plus one of two immunosuppressant regimens) compared with placebo added to SOC in patients with WHO or ISN Class III or IV lupus nephritis.
提供机构：
Vivli
创建时间：
2020-05-05
